



6-27-05

EXPRESS MAIL NO. EV530946136US

TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

	Application Number	10/647,720
	Filing Date	August 25, 2003
	First Named Inventor	Christine Markert-Hahn
	Art Unit	1645
	Examiner Name	
	Attorney Docket No.	810102.401

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address (2) <input type="checkbox"/> Declaration <input checked="" type="checkbox"/> Statement under 37 CFR 3.73(b) (2) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
---	---	--

2 Copies of assignment (one attached to each Statement Under 37 CFR 3.73(b))

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Seed Intellectual Property Law Group PLLC	Customer Number	00500
Signature			
Printed Name	Karl R. Hermanns		
Date	June 24, 2005	Reg. No.	33,507

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature		
Typed or printed name		Date:

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL NO.
EV530946136US

PTO/SB/82 (09-04)

Approved for use through 11/30/2005. OMB 0651-0035
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



**REVOCATION OF POWER
OF ATTORNEY WITH
NEW POWER OF ATTORNEY
AND CHANGE OF
CORRESPONDENCE ADDRESS**

Application Number	10/647,720
Filing Date	August 25, 2003
First Named Inventor	Christine Markert-Hahn
Art Unit	1645
Examiner Name	
Attorney Docket Number	810102.401

I hereby revoke all previous powers of attorney given in the above-identified application:

A Power of Attorney is submitted herewith.

OR

I hereby appoint the practitioners at Seed IP Law Group PLLC, Customer Number: **00500**

Please change the correspondence address for the above-identified application to:

The address associated with Customer Number: **00500**

OR

<input type="checkbox"/> Firm or Individual Name				
Address				
City				
Country	State		ZIP	
Telephone	Fax			

I am the:

Applicant/Inventor.

Assignee of record of a 50% interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

As assignee of record of a 50% interest I/we hereby elect, under 37 CFR 3.71,
to prosecute the application to the exclusion of the inventor(s).

SIGNATURE of Applicant or Assignee of Record

Signature	
Name	MELINDA GRIFFITH Senior Vice President & General Counsel
Date	May 31, 2005

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.
Submit multiple forms if more than one signature is required, see below*.

*Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL NO.
EV530946136US

PTO/SB/82 (09-04)

Approved for use through 11/30/2005. OMB 0651-0035

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

JUN 24 2005

REVOCA^TON OF POWER
OF ATTORNEY WITH
NEW POWER OF ATTORNEY
AND CHANGE OF
CORRESPONDENCE ADDRESS

Application Number	10/647,720
Filing Date	August 25, 2003
First Named Inventor	Christine Markert-Hahn
Art Unit	1645
Examiner Name	
Attorney Docket Number	810102.401

I hereby revoke all previous powers of attorney given in the above-identified application:

A Power of Attorney is submitted herewith.

OR

I hereby appoint the practitioners at Seed IP Law Group PLLC, Customer Number: **00500**

Please change the correspondence address for the above-identified application to:

The address associated with Customer Number **00500**

OR

<input type="checkbox"/> Firm or Individual Name				
Address				
City				
Country	State		ZIP	
Telephone	Fax			


I am the:

Applicant/Inventor.

Assignee of record of a 50% interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

As assignee of record of a 50% interest I/we hereby elect, under 37 CFR 3.71,
to prosecute the application to the exclusion of the inventor(s).

SIGNATURE of Applicant or Assignee of Record

Signature		
Name	Dr. Kurt Berlin	Aron Braun
Date	May 30, 2005	

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.
Submit multiple forms if more than one signature is required, see below*.

*Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

572182_1.DOC

EXPRESS MAIL NO.
EV530946136US

PTO/SB/96 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Christine Markert-Hahn et al.

Application No./Patent No.: 10/647,720 Filed/Issue Date: August 25, 2003

Entitled: METHOD FOR BISULFITE TREATMENT

Roche Molecular Systems Inc. a **corporation**

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership,
university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is 50%

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above.
The assignment was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Inventors To: Roche Molecular Systems Inc.

The document was recorded in the United States Patent and Trademark Office at
Reel 015033, Frame 0833, or for which a copy thereof is attached.

2. From: Roche Molecular Systems Inc. To: Epigenomics AG [50% assigned]

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title noted in B above are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08.]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature
Melinda Griffith

Typed or printed name

April 22, 2005

Date
SVP and General Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 810102.401

572183_1.DOC

ASSIGNMENT

WHEREAS, Roche Molecular Systems Inc. (hereinafter referred to as ASSIGNOR), a Delaware corporation have a place of business at 1145 Atlantic Avenue, Alameda, California 94501, is the assignee of record of an invention entitled "METHOD FOR BISULFITE TREATMENT," as described and claimed in the specification for which an application for United States letters patent was filed on August 25, 2003, and assigned Application No. 10/647,720; This application claims priority to EPAN 02019097.1 filed August 29, 2002 and EPAN 02028114.3, filed December 18, 2002.

WHEREAS, Epigenomics AG (hereinafter referred to as ASSIGNEE), a German corporation having a place of business at Kleine Praesidentenstrasse 1, 10178 Berlin, Germany, is desirous of acquiring a fifty percent (50%) right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE a fifty percent (50%) right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign

letters patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

ROCHE MOLECULAR SYSTEMS INC.

April 22, 2005

Date

By

Name: Melinda Griffith
Title: Senior Vice President & General Counsel


STATE OF CALIFORNIA)
) ss.
COUNTY OF ALAMEDA)

On April 22, 2005, before me, Winsome St. Rose, Notary Public, personally appeared MELINDA GRIFFITH, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he signed this instrument, on oath stated that he was authorized to execute the instrument, and acknowledged it as the SVP & General Counsel of **Roche Molecular Systems Inc.** to be the free and voluntary act of such party for the uses and purposes mentioned in the instrument.

WITNESS my hand and official seal.

(Seal)

Notary Public for the State of California
Printed Name: Winsome A. St. Rose
My Commission Expires Jan. 13, 2006



572176_1.DOC

O I P E
JUN 24 2005
PATENT & TRADEMARK OFFICE
**EXPRESS MAIL NO.
EV530946136US**

PTO/SB/96 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Christine Markert-Hahn et al.

Application No./Patent No.: 10/647,720 Filed/Issue Date: August 25, 2003

Entitled: METHOD FOR BISULFITE TREATMENT

Epigenomics AG a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership,
university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is 50%

in the patent application/patent identified above by virtue of either:

- A. An assignment from the inventor(s) of the patent application/patent identified above.
The assignment was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
OR
- B. A chain of title from the inventor(s), of the patent application/patent identified above, to the
current assignee as shown below:

1. From: Inventors To: Roche Molecular Systems Inc.

The document was recorded in the United States Patent and Trademark Office at
Reel 015033, Frame 0833, or for which a copy thereof is attached.

2. From: Roche Molecular Systems Inc. To: Epigenomics AG [50% assigned]

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____


The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.


Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title noted in B above are
attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment
Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See
MPEP 302.08.]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.


Signature


Date

Dr. Kurt Berlin
Typed or printed name

Aron Braun
Title

-CSO-

-COO-

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 810102.401

572184_1.DOC

ASSIGNMENT

WHEREAS, Roche Molecular Systems Inc. (hereinafter referred to as ASSIGNOR), a Delaware corporation have a place of business at 1145 Atlantic Avenue, Alameda, California 94501, is the assignee of record of an invention entitled "METHOD FOR BISULFITE TREATMENT," as described and claimed in the specification for which an application for United States letters patent was filed on August 25, 2003, and assigned Application No. 10/647,720; This application claims priority to EPAN 02019097.1 filed August 29, 2002 and EPAN 02028114.3, filed December 18, 2002.

WHEREAS, Epigenomics AG (hereinafter referred to as ASSIGNEE), a German corporation having a place of business at Kleine Praesidentenstrasse 1, 10178 Berlin, Germany, is desirous of acquiring a fifty percent (50%) right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE a fifty percent (50%) right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign

letters patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

ROCHE MOLECULAR SYSTEMS INC.

April 22, 2005
Date

By Melinda Griffith
Name: Melinda Griffith
Title: Senior Vice President & General Counsel

STATE OF CALIFORNIA)
) ss.
COUNTY OF ALAMEDA)

On April 22, 2005, before me, Winsome St. Rose, Notary Public, personally appeared MELINDA GRIFFITH, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he signed this instrument, on oath stated that he was authorized to execute the instrument, and acknowledged it as the SVP & General Counsel of **Roche Molecular Systems Inc.** to be the free and voluntary act of such party for the uses and purposes mentioned in the instrument.

WITNESS my hand and official seal.

(Seal)

Notary Public for the State of California
Printed Name: Winsome A. St. Rose
My Commission Expires Jan. 13, 2006

